Executive Interviews

  1. Can David Hung Lead Axovant To Alzheimer’s Success?
    10/10/2017

    Why would David Hung, M.D., a veteran pharma executive, forgo retirement (after a big acquisition payday), join Axovant Sciences, and then invest $10 million of his own money into the small company? Our chief editor sat down with him to get the answers to those questions and more.

  2. Can We Make Innovative Medicines Affordable?
    10/10/2017

    “As the price of pharmaceuticals continues to rise, we are seeing greater resistance from [U.S.] patients being willing to pay,” says Dr. Steven Miller. The SVP and chief medical officer at Express Scripts is giving his opening remarks during the Our Common Goal: Ensuring Access and Affordability of Innovative Medicines session at the 2017 BIO International Convention in San Diego. Miller pulls no punches with his fellow biopharmaceutical executive panelists, setting the tone that today’s discussion on drug pricing will not be a “hugfest.”

  3. Prometic: New Tech Harvests Orphan Treatments
    10/10/2017

    Always stick with your original goals, even when you reap another, off-the-scale success. Like many biopharma companies, Prometic invented a novel technology platform, initially to make new medicines available to unserved populations.

  4. Behind The Scenes Of Allergan’s Social Contract
    9/8/2017

    The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.

  5. P3s: How To Get The Good …Without The Bad
    9/8/2017

    At this year’s BIO International Convention in San Diego (June 19 – 22), I moderated a session, Navigating A Clear Path To Public-Private Partnerships, and we talked about the good, the bad, and the ugly of P3s. After a brief introduction, the first question was posed, resulting in the following edited dialogue.

  6. Cytokinetics: Keeping Its Sights On Independence
    9/8/2017

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.